Hemobrás

What Hemobrás does

Hemobrás (Empresa Brasileira de Hemoderivados e Biotecnologia) is a Brazilian state-owned pharmaceutical company (empresa pública) linked to the Ministry of Health, established to manufacture blood-derived and biotechnological medicines for the Brazilian public health system (SUS). The company operates two manufacturing facilities in Goiana, Pernambuco: a hemoderivatives plant producing medicines from fractionated human plasma, and a biotechnological medicines plant using recombinant DNA technology. Its product portfolio includes Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante (Hemo-8r), with Hemo-8r being the first product registered under the Hemobrás brand. It also lists Complexo Protrombínico and Fator de von Willebrand in its broader portfolio.

The company generates revenue exclusively through government procurement contracts with the Ministry of Health, supplying five essential medicines to the SUS for treatment of hemophilia, burns, immunological disorders, and blood clotting disorders. Raw material supply is sourced through the Hemorrede Qualificada, a nationwide network of public and private hemotherapy services that Hemobrás manages under Portaria 1.710/2020. Core manufacturing technology is acquired through technology transfer agreements with LFB (France) for hemoderivatives and Takeda (Japan) for recombinant products, rather than through proprietary R&D. In 2022, the company delivered 82,981 bottles across its portfolio.

Hemobrás operates as a government monopoly supplier within a single-customer, single-country framework: its sole customer is the SUS, and its sole market is Brazil. This structure provides structural revenue stability and regulatory protection but eliminates commercial competition, diversified revenue streams, and growth optionality typical of market-driven pharmaceutical companies. Pricing is determined through public procurement processes and is not publicly disclosed. The company has no external private investors, no funding rounds, and no M&A activity; its capital structure is wholly government-funded.

Name

Hemobrás

Legal name

Empresa Brasileira de Hemoderivados e Biotecnologia

Website

https://hemobras.gov.br

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

Hemobrás is a Brazilian state-owned pharmaceutical company that manufactures hemoderivatives and biotechnological medicines exclusively for the Brazilian public health system (SUS), producing five essential medicines including Albumin, Immunoglobulin, and clotting factors for hemophilia treatment from its Goiana (PE) facilities.

Ownership category

akta.pro rank

Product category

Hemoderivative and Biotechnological Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived & Blood Products Distributors (HLAIAJAJ)

Keywords

• Hemoderivative medicines
• Biotechnological pharmaceuticals
• Plasma fractionation
• Recombinant medicines
• Public health supply

Headquarters

HQ city

Brasilândia

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. SUS Medicine Supply: Hemobrás supplies five medicines to the Brazilian public health system (SUS): Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante (Hemo-8r). Revenue is generated through government procurement contracts with the Ministry of Health.
2. Plasma Collection and Management: Hemobrás manages the Brazilian plasma supply through the Hemorrede Qualificada, collecting raw material for hemoderivative production from public and private hemotherapy services across the country under Portaria 1.710/2020.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Hemobrás is a state-owned pharmaceutical company that researches, develops, and produces hemoderivative and biotechnological medicines for Brazil's public health system (SUS). It manufactures five core medicines (Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante/Hemo-8r) using plasma fractionation and recombinant DNA technology at its manufacturing complex in Goiana, Pernambuco. The company also manages Brazil's national plasma supply through the Hemorrede Qualificada under Ministry of Health ordinance.

Product overview

Hemobrás operates two manufacturing facilities in Goiana, PE, Brazil: a hemoderivatives factory and a biotechnological medicines factory. The company produces and supplies five medicines to Brazil's Unified Health System (SUS): Albumin, Immunoglobulin, Plasma-derived Factor VIII and Factor IX, and Recombinant Factor VIII (Hemo-8r). Hemoderivatives are produced from human plasma collected via Brazil's qualified hemotherapy network. Recombinant products use DNA recombinant technology through genetic engineering. The company holds technology transfer agreements with French biotech company LFB (for hemoderivatives) and Takeda (for recombinant Hemo-8r).

Differentiator

Problem solved

Functional benefit

Products and services

• Hemo-8r (Fator VIII Recombinante)

Quantifiable outcome

• 82,981 bottles delivered in 2022

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• LFB (Laboratoire Français de Biotechnologie)coreStrategic or Co-development PartnerLFB is a French biotechnology laboratory and a strategic technology transfer partner for Hemobrás. The partnership involves transfer of technology for the production of hemoderivative medicines including Albumina, Complexo Protrombínico, Fator VIII e IX da coagulação, Fator de von Willebrand, and Imunoglobulina. This is a core partnership enabling domestic production of plasma-derived medicines in Brazil.
• TakedacoreStrategic or Co-development PartnerTakeda is a Japanese pharmaceutical company engaged in technology transfer with Hemobrás for the production of recombinant medicines. Currently, there is an ongoing technology transfer process with Takeda for the production of Hemo-8r (Fator VIII recombinante), Hemobrás' first registered product. This partnership enables domestic production of recombinant blood clotting factors.
• Hemorrede Qualificada (Qualified Blood Network)coreOthersThe Hemorrede Qualificada is a network of public and private hemotherapy services across Brazil that supply plasma to Hemobrás for the production of hemoderivative medicines. Under Portaria 1.710/2020, Hemobrás is responsible for managing Brazilian plasma, collecting raw material from services nationwide.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Roche (Chugai): Global pharmaceutical company with a major hemophilia franchise (including recombinant Factor VIII via Chugai/Genentech). Comparable in recombinant coagulation factor manufacturing and global hemophilia market presence.
• Grifols: Global leader in plasma-derived therapies and a major supplier of hemoderivatives (immunoglobulin, coagulation factors, albumin). Comparable in plasma fractionation manufacturing and recombinant product portfolio.
• CSL Behring: Global plasma-derived therapies business of CSL Limited, producing coagulation factors, immunoglobulins, and albumin. Highly comparable to Hemobrás's hemoderivatives portfolio and plasma fractionation operations.
• Takeda: Japanese pharmaceutical company and Hemobrás's technology transfer partner for recombinant Factor VIII (Hemo-8r). Comparable in recombinant coagulation factor manufacturing and global hemophilia franchise.
• Sanofi (Hemophilia Franchise): Global pharmaceutical company with a significant hemophilia and rare disease franchise, including recombinant and plasma-derived coagulation factors. Comparable in recombinant Factor VIII and hemophilia therapeutic offerings.
• Octapharma: Swiss-headquartered manufacturer of plasma-derived medicines (coagulation factors, immunoglobulins, albumin). Comparable in core plasma fractionation and hemophilia therapy product lines.

Direct peers

• Kedrion Biopharma: Italy-based plasma-derived therapies manufacturer with a similar national-champion profile (Italian National Blood Center partnership). Directly comparable in plasma fractionation and supply of hemoderivatives to a national health system.
• Bio Products Laboratory (BPL): UK-based plasma fractionator producing coagulation factors, albumin, and immunoglobulins. Comparable in plasma-derived product portfolio and national/regional public health supply role.
• LFB (Laboratoire Français de Biotechnologie): French state-influenced plasma fractionator that is Hemobrás's core technology transfer partner for hemoderivative production (Albumin, Immunoglobulin, coagulation factors). Directly comparable in plasma-derived medicines manufacturing and national public-health mission.

Regional players

• Instituto Butantan: Brazilian state-owned biomedical institute producing vaccines and biopharmaceuticals. Comparable as a Brazilian public-sector biomanufacturer with a national health system mission similar to Hemobrás.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/hemobras_ms
• YouTubeyoutube.com/channel/UCuryaNuxQNQ17UGjIgzb8Nw
• Facebookfacebook.com/hemobras
• LinkedInlinkedin.com/company/hemobras-oficial
• Instagraminstagram.com/hemobras

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemobrás